Navigation Links
Opexa Therapeutics Reports Positive Top-line Data in Phase I/II,Dose Escalation Trial with Tovaxin for Multiple Sclerosis

THE WOODLANDS, Texas--(BUSINESS WIRE)--Apr 3, 2007 - Opexa Therapeutics, Inc. (NASDAQ: OPXA), a company involved in the development and commercialization of cell therapies, today announced positive top-line data in an open-label Phase I/II dose escalation clinical trial of the investigational T-cell vaccine, Tovaxin(TM), for multiple sclerosis. In this one-year, 10-subject dose escalation clinical trial, Tovaxin therapy was shown to be safe and effective. The "per-protocol" analysis of Tovaxin therapy achieved a 90% reduction (p = 0.0039) in annualized relapse rate (ARR) in subjects who received one of the three dosage levels; the doses were 6 - 9 x 10(6), 30 - 45 x 10(6) or 60 - 90 x 10(6) attenuated T-cells. Subjects in the study received subcutaneous injections of Tovaxin over a period of 20 weeks (0, 4, 12 and 20 weeks) and were monitored for an additional 32 weeks.

The safety profile for all dosage levels revealed no severe adverse reactions related to T-cell vaccination. With increasing dosage, an increase in mild injection site reactions was observed and these resolved within 48 hours.

All subjects currently are enrolled in an extension study to collect longitudinal safety and effectiveness data.

David McWilliams, president and chief executive officer of Opexa, commented, "We are particularly encouraged by the data from this dose escalation trial. While all three dosage levels were safe and effective, the group treated with the 30 - 45 x 10(6) T-cell dose achieved a 100% reduction in ARR. The currently enrolling Tovaxin IIb clinical trial is being conducted with the 30 - 45 x 10(6) T-cell dose."

About TERMS

The Tovaxin Phase IIb clinical study will include 150 patients in a multicenter, randomized, double blind, placebo-controlled trial designed primarily to evaluate the efficacy, safety and tolerability of the Tovaxin T- cell vaccination with clinically isolated syndrome (CIS
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Opexa Advances Monocyte Derived Islet Technology to Proof of Principle in stz-induced NOD/SCID Mice
2. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
3. Opexa Presents Tovaxin Research at Federation of Clinical Immunology Societies Annual Meeting
4. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
5. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
6. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
7. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
8. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
9. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
Post Your Comments:
(Date:4/17/2015)... , April 17, 2015  AbbVie Inc. ("AbbVie") (NYSE ... that it has extended the expiration of its exchange offer ... of Pharmacyclics, Inc. to 5 p.m., New York ... On April 17, 2015, AbbVie also voluntarily withdrew its ... Act in order to provide the FTC with additional time ...
(Date:4/17/2015)... Research and Markets ( http://www.researchandmarkets.com/research/6tdwh8/medical_device ... "Medical Device Outsourcing - Global Strategic Business Report" ... report analyzes the worldwide markets for Medical Device ... Categories: Class I, Class II, and Class III. ... Include - Radiology, Orthopedic, Neurology, Cardiology, and Others. ...
(Date:4/17/2015)... , April 17, 2015 ASSESS ... mutation   is a viable alternative to tumour biopsy   ... in all patients with advanced NSCLC   AstraZeneca ... of plasma circulating tumour DNA (ctDNA) testing for epidermal growth ... advanced non-small cell lung cancer (NSCLC) in clinical practice. [ ...
Breaking Medicine Technology:AbbVie Extends Exchange Offer to Acquire Pharmacyclics, Inc. 2AbbVie Extends Exchange Offer to Acquire Pharmacyclics, Inc. 3AbbVie Extends Exchange Offer to Acquire Pharmacyclics, Inc. 4Medical Device Outsourcing (Radiology, Orthopedic, Neurology, Cardiology, and Others) Market 2015 - Global Strategic Business Report 2Medical Device Outsourcing (Radiology, Orthopedic, Neurology, Cardiology, and Others) Market 2015 - Global Strategic Business Report 3"Real World" Data Support Use of Blood Test for EGFR Mutation in Advanced NSCLC 2"Real World" Data Support Use of Blood Test for EGFR Mutation in Advanced NSCLC 3"Real World" Data Support Use of Blood Test for EGFR Mutation in Advanced NSCLC 4
... 2007 - Ceragenix Pharmaceuticals,Inc. (OTCBB:CGXP), a biopharmaceutical ... announced that a catheter,treated with a Ceragenin ... 21 day study., In the study, polyurethane ... a phosphate-suffered solution along with an,untreated catheter. ...
... PGL; NASDAQ: PGLA) is pleased to announce that its ... late breaking news,presentation by the European Association for the ... the results of this liver,cancer trial at the American ... ,In expectation of having final data fully analysed and ...
Cached Medicine Technology:Ceragenix Announces Ceragenins Virtually Prevent Catheter Biofilm,Formation in 21 Day Study 2Ceragenix Announces Ceragenins Virtually Prevent Catheter Biofilm,Formation in 21 Day Study 3PI-88 Data to be Presented at Key International Conferences 2PI-88 Data to be Presented at Key International Conferences 3
(Date:4/18/2015)... Carinsurancesavings.biz has released a new blog ... cheaper during Spring. , Spring can be a ... should make sure they compare the newest policies before ... learn more about Spring car insurance offers by reading ... quotes are becoming more and more popular. Many insurance ...
(Date:4/18/2015)... 2015 "I wanted to live ... a healthful juice that contained essential vitamins, minerals ... "It increases my energy, improves skin elasticity and ... developed Tapp's Juice to contain fruits, vegetables and ... physical and mental fatigue. It features a great ...
(Date:4/18/2015)... 2015 Lowcostcarinsuranceprice.com has released a new ... on auto insurance prices . , Drivers ... vehicle theft may have to pay more for auto ... insurance policies can also offer protection against vehicle theft. ... compared online on a single website: http://lowcostcarinsuranceprice.com/ ...
(Date:4/18/2015)... 18, 2015 Thousand of DePuy Pinnacle ... of individuals who were allegedly harmed by a metal-on-metal ... forward in the U.S. District Court, Northern District of ... Court has amended an earlier Case Management Order to ... things, the new amendment permits the claims of up ...
(Date:4/18/2015)... 2015 On April 14th, 2015, Symantec released ... which they say, “exposes a tactical shift by cyberattackers.” With ... were introduced in 2014 - almost a million a day ... to be identified and patched by prominent manufacturers – as ... doing business in a digital world can be fraught with ...
Breaking Medicine News(10 mins):Health News:Auto Insurance Plans Are Cheaper During Spring! 2Health News:High Rates Of Car Theft Can Have An Impact on Auto Insurance Prices! 2Health News:DePuy Pinnacle Hip Lawsuits: Federal Litigation Amends Case Management Order to Allow for Joinder of Unrelated Claims 2Health News:DePuy Pinnacle Hip Lawsuits: Federal Litigation Amends Case Management Order to Allow for Joinder of Unrelated Claims 3Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 2Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 3Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 4Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 5
... Sheriff Adrian Garcia will deliver the keynote address, "The Harris ... 9 a.m., Friday (March 2) at the University of Houston ... attend the keynote address. A question-and-answer period will follow. ... Houston Area Social Work Awards Breakfast hosted by the UH ...
... A new method for creating nanofibers made of proteins, ... University (NYU-Poly), promises to greatly improve drug delivery methods ... disease, as well as aid in the regeneration of ... differently, this same development could point the way to ...
... release is available in French . ... CHUM Hospital,s International Health, will be joining the World Health ... funding of the fight against Noma. This disease, scientifically called ... Sub-Saharan Africa. Despite the existence of a cheap and easy ...
... By Steven Reinberg HealthDay Reporter , ... bring their children to the emergency room with fevers ... "Self-referred febrile [feverish] children should not be generalized, and ... ill patients," said lead researcher Dr. Yvette van Ierland, ...
... Exposure to bisphenol A (BPA), a controversial chemical commonly used ... disease later in life, a new study suggests. ... drinks, but also may be exposed through drinking water, dental ... researchers compared BPA levels in 758 people who were initially ...
... TAMPA, Fla. -- Researchers at Moffitt Cancer Center ... that the XL888 inhibitor can prevent resistance to the ... melanoma. Vemurafenib resistance is characterized by a diminished ... researchers, the balance between apoptosis and cell survival is ...
Cached Medicine News:Health News:Sheriff Adrian Garcia delivers keynote at social work awards breakfast 2Health News:Nanofiber breakthrough holds promise for medicine and microprocessors 2Health News:Montrealer heads to Congo to fight childhood disfigurement 2Health News:Parents Often Right to Bring Kids With Fever to the ER: Study 2Health News:Parents Often Right to Bring Kids With Fever to the ER: Study 3Health News:BPA Exposure May Raise Risk of Heart Disease 2Health News:Researchers find potential solution to melanoma's resistance to vemurafenib 2
... CoaguChek System has been providing accurate, reliable PT/INR ... point of care. , The CoaguChek System is ... self-testing when monitoring on Coumadin (warfarin sodium) therapy. ... a result from a fingerstick drop (10ul) of ...
The QuickScreen Pro Multi Drug Screening Test is a rapid, self-timing, qualitative immunoassay for,the detection of drugs of abuse in urine....
... The ADC drugs of abuse tests are ... at the SAMHSA recommended cut-off as confirmed by ... result. A more specific alternative method (such as ... a confirmed result. Professional judgment should be applied ...
The Osteomark NTx Point of Care (POC)device allows physicians to monitor their patients response to anti-resorptive drugs as early as 3-6 months from starting treatment. Osteomark NTx shows you and y...
Medicine Products: